Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03508011 | A Study of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 57 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02142608 | A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Bracco Diagnostics, IncINDUSTRY | 2 | Mar 29, 2021 | clinicaltrials |
| Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer |
| completed |
| Phase 1 / Phase 2 |
| 18 |
| Barbara Ann Karmanos Cancer InstituteOTHER |
| 1 |
| Mar 25, 2021 |
| clinicaltrials |
| NCT00538668 | Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody | completed | Phase 1 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT01784757 | Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer(ARAFOR) | completed | Phase 1 | 30 | Orion Corporation, Orion PharmaINDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT02411786 | A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF | completed | Phase 1 | 40 | University of Wisconsin, MadisonOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02004418 | A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland(PET PRO) | completed | Phase 1 / Phase 2 | 21 | AHS Cancer Control AlbertaOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02179515 | Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | completed | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT02730975 | Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer(ABIFOOD01) | completed | Phase 1 | 42 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT01646684 | Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer | completed | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00663832 | A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer | completed | Phase 1 | 44 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01634061 | Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | completed | Phase 1 | 43 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT02883166 | Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake(SNACK) | completed | Phase 1 | 14 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT03774056 | A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. | completed | Phase 1 | 43 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03778047 | A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch | completed | Phase 1 | 10 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03183544 | Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit(PSMA) | completed | Phase 1 | 3 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT02472275 | PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | completed | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02693860 | Neoadjuvant J591 Treatment for Prostate Cancer | completed | Phase 1 | 8 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT03384316 | Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2020 | clinicaltrials |
| NCT00959959 | ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer(ARMOR1) | completed | Phase 1 | 49 | LTN PHARMACEUTICALS, INC.INDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT01931046 | Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 28 | Momotaro-Gene Inc.INDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT00064129 | Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2020 | clinicaltrials |
| NCT02092948 | Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer | completed | Phase 1 | 8 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT03362359 | Ga-68-PSMA-11 in High-risk Prostate Cancer | completed | Phase 1 / Phase 2 | 173 | German Cancer Research CenterOTHER | 2 | Jul 27, 2020 | clinicaltrials |
| NCT02747342 | A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer | completed | Phase 1 | 33 | Atridia Pty Ltd.INDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT02924766 | A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE) | completed | Phase 1 | 34 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 20, 2020 | clinicaltrials |
| NCT03199872 | RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours | completed | Phase 1 / Phase 2 | 22 | RhoVac APSINDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT00105053 | Vaccine Treatment for Hormone Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 8 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02151760 | Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer | completed | Phase 1 | 37 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 7, 2020 | clinicaltrials |
| NCT03497377 | Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer. | completed | Phase 1 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 7, 2020 | clinicaltrials |
| NCT02162836 | A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 6 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Apr 27, 2020 | clinicaltrials |
| NCT02285101 | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | completed | Phase 1 | 23 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT02036918 | Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 1 | 20 | Duke UniversityOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT03618355 | Trial of eRapa in Prostate Cancer Patients | completed | Phase 1 | 15 | Rapamycin Holdings, Inc. dba Emtora BiosciencesINDUSTRY | 1 | Mar 31, 2020 | clinicaltrials |
| NCT03264456 | Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI | completed | Phase 1 / Phase 2 | 18 | University of Alabama at BirminghamOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT01923727 | Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer(IAB2M) | completed | Phase 1 / Phase 2 | 38 | ImaginAb, Inc.INDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02390063 | Vaccination in Prostate Cancer (VANCE) | completed | Phase 1 | 40 | University of OxfordOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02991911 | A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer(MEDI3726) | completed | Phase 1 | 33 | MedImmune LLCINDUSTRY | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00002602 | Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer | completed | Phase 1 / Phase 2 | 1,084 | Radiation Therapy Oncology GroupNETWORK | 2 | Jan 10, 2020 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT02344017 | Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer(DUALIDES) | completed | Phase 1 / Phase 2 | 23 | Orion Corporation, Orion PharmaINDUSTRY | 4 | Dec 19, 2019 | clinicaltrials |
| NCT00036790 | Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer | completed | Phase 1 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00113984 | Vaccine and Antibody Treatment of Prostate Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT02946008 | Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer | completed | Phase 1 | 17 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 27, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Mar 30, 2021source: clinicaltrials